Document is current
Any future updates will be listed below
-
Authors
Sharma, Ashish https://orcid.org/0000-0002-8550-9791
Loewenstein, Anat https://orcid.org/0000-0002-7706-1165
Parachuri, Nikulaa
Kumar, Nilesh https://orcid.org/0000-0002-7439-2081
Rasal, Alok
Bandello, Francesco https://orcid.org/0000-0003-3238-9682
Kuppermann, Baruch D.
- License Information
-
More Information
Article History
Received: 7 July 2023
Revised: 24 July 2023
Accepted: 2 August 2023
First Online: 30 August 2023
Competing interests
: AS: CONSULTANT: for Novartis, Allergan, Bayer, Lupin and Intas, Speaker fee Biogen. AL: CONSULTANT: Allergan, Novartis, Roche, Notal Vision, Fiorsightslabs, Beyeonics, Bayer Health Care. AR: Employee Intas Pharmaceuticals Ltd. FB: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK: CLINICAL RESEARCH:, Alimera, Allegro, Allergan, Apellis, Boehringer Ingelheim, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron; CONSULTANT: Alimera, Allegro, Allergan/AbbVie, Boehringer Ingelheim, Clearside, Coherus, EyeBio, Eyedaptic, Galimedix, Genentech, Glaukos, IvericBio, jCyte, Novartis, Ocular Therapeutix, Regeneron, Revana, Theravance Biopharma. The other authors declare no competing interests.
